Lataa...

Development of [(89)Zr]DFO-elotuzumab for immunoPET imaging of CS1 in multiple myeloma

PURPOSE. Multiple myeloma (MM) is a bone marrow malignancy that remains mostly incurable. Elotuzumab is an FDA-approved therapeutic monoclonal antibody targeted to the cell surface glycoprotein CS1, which is overexpressed in MM cells. Identifying patients who will respond to CS1 targeted treatments...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Eur J Nucl Med Mol Imaging
Päätekijät: Ghai, Anchal, Zheleznyak, Alexander, Mixdorf, Matt, O’Neal, Julie, Ritchey, Julie, Rettig, Michael, DiPersio, John, Shokeen, Monica, Achilefu, Samuel
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2020
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8110592/
https://ncbi.nlm.nih.gov/pubmed/33179150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-020-05097-y
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!